Crenolanib was evaluated in a phase II study among patients with FLT3-mutated AML in the relapsed/refractory setting (median 3.5 prior therapies); at a median follow up of 14 weeks, the ORR was 47%, with a 12% CRi [36]. Here, FLT3 is linked to acute myeloid leukemia.